1-10 of 10
Johanna Bendell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data
Journal Articles

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

Ming Lei, Nathan O. Siemers, Dimple Pandya, Han Chang, Teresa Sanchez, Christopher Harbison, Peter M. Szabo, Yelena Janjigian, Patrick A. Ott, Padmanee Sharma, Johanna Bendell, Thomas R. Jeffry Evans, Filippo de Braud, Ian Chau, Zachary Boyd
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3926–3935.
https://doi.org/10.1158/1078-0432.CCR-20-2790
Published: 15 July 2021
View article titled, Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Open the PDF for Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung-Jue Bang, Chia-Chi Lin, Wu-Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, Michelle Carlsen, Shelly Schmidt, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1267–1277.
https://doi.org/10.1158/1078-0432.CCR-20-2821
Published: 01 March 2021
View article titled, Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Open the PDF for Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, Patricia LoRusso, Johanna Bendell, Shih-Min A. Huang, Marie-Claire Wagle, Kwame Okrah, Lichuan Liu, Elaine Murray, Sandra M. Sanabria-Bohorquez, Michael Tagen, Hatem Dokainish, Lars Mueller, Howard Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1229–1236.
https://doi.org/10.1158/1078-0432.CCR-19-2574
Published: 13 March 2020
View article titled, A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

David S. Hong, Kathleen Moore, Manish Patel, Stefan C. Grant, Howard A. Burris, III, William N. William, Jr, Suzanne Jones, Funda Meric-Bernstam, Jeffrey Infante, Lisa Golden, Wei Zhang, Ricardo Martinez, Sameera Wijayawardana, Richard Beckmann, Aimee Bence Lin, Cathy Eng, Johanna Bendell
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3263–3272.
https://doi.org/10.1158/1078-0432.CCR-17-3347
Published: 15 July 2018
View article titled, Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
Open the PDF for Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

Johanna Bendell, Valerie Andre, Alan Ho, Ragini Kudchadkar, Michael Migden, Jeffrey Infante, Ramon V. Tiu, Celine Pitou, Trevor Tucker, Les Brail, Daniel Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (9): 2082–2091.
https://doi.org/10.1158/1078-0432.CCR-17-0723
Published: 30 April 2018
View article titled, Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma
Open the PDF for Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma in another window
Journal Articles

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody

George A. Dominguez, Thomas Condamine, Sridevi Mony, Ayumi Hashimoto, Fang Wang, Qin Liu, Andres Forero, Johanna Bendell, Robert Witt, Neil Hockstein, Prasanna Kumar, Dmitry I. Gabrilovich
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 2942–2950.
https://doi.org/10.1158/1078-0432.CCR-16-1784
Published: 14 June 2017
View article titled, Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
Open the PDF for Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Geoffrey I. Shapiro, Katherine M. Bell-McGuinn, Julian R. Molina, Johanna Bendell, James Spicer, Eunice L. Kwak, Susan S. Pandya, Robert Millham, Gary Borzillo, Kristen J. Pierce, Lixin Han, Brett E. Houk, Jorge D. Gallo, Maria Alsina, Irene Braña, Josep Tabernero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1888–1895.
https://doi.org/10.1158/1078-0432.CCR-14-1306
Published: 14 April 2015
View article titled, First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Open the PDF for First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of pharmacokinetic interaction between everolimus and erlotinib in patients with advanced cancer

William Petros, Karen Bullock, Hope Uronis, Dorris Lockamy, Leigh Howard, Islam Younis, Gloria Broadwater, Herbert Hurwitz, Johanna Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): B3.
Published: 15 August 2014
View article titled, Evaluation of pharmacokinetic interaction between everolimus and erlotinib in patients with advanced cancer
Journal Articles

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Cristina Saura, Johanna Bendell, Guy Jerusalem, Shaun Su, Qinhua Ru, Stefan De Buck, David Mills, Sophie Ruquet, Ana Bosch, Ander Urruticoechea, Joseph T. Beck, Emmanuelle Di Tomaso, David W. Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, Jose Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1935–1945.
https://doi.org/10.1158/1078-0432.CCR-13-1070
Published: 31 March 2014
View article titled, Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Open the PDF for Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy in another window
Includes: Supplementary data